ANIP analyst estimates
ANI Pharmaceuticals (ANIP) analyst ratings, the average price target and its range, and every firm's latest call.
ANIP analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | ANI Pharmaceuticals initiated with a Perform at Oppenheimer | $85.00 |
| Sep 9, 2026 | Leerink Partners | ANI Pharmaceuticals initiated with an Outperform at Leerink | $104.00 |
| Aug 10, 2026 | Canaccord Genuity | ANI Pharmaceuticals price target lowered to $90 from $91 at Canaccord | $90.00 |
| Aug 10, 2026 | Guggenheim | ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim | $119.00 |
| Jul 16, 2026 | Canaccord Genuity | ANI Pharmaceuticals initiated with a Hold at Canaccord | $91.00 |
| Jan 16, 2026 | Guggenheim | ANI Pharmaceuticals (ANIP) PT Raised to $124 at Guggenheim | $124.00 |
| Oct 9, 2025 | Truist Financial | ANI Pharmaceuticals price target raised to $90 from $77 at Truist | $90.00 |
| Sep 17, 2025 | H.C. Wainwright | ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright | $121.00 |
| Sep 8, 2025 | Guggenheim | ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim | $114.00 |
| Aug 8, 2025 | Piper Sandler | ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler | $94.00 |
| Mar 5, 2025 | Guggenheim | ANI Pharmaceuticals price target raised to $86 from $84 at Guggenheim | $86.00 |
| Sep 18, 2024 | Raymond James | ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James | $83.00 |
| Sep 11, 2024 | Truist Financial | ANI Pharmaceuticals downgraded to Hold from Buy at Truist | $60.00 |
| Jun 26, 2024 | H.C. Wainwright | ANI Pharmaceuticals (ANIP) PT Raised to $94 at H.C. Wainwright | $94.00 |
| May 13, 2024 | H.C. Wainwright | ANI Pharmaceuticals (ANIP) PT Raised to $87 at H.C. Wainwright | $87.00 |
- 4 firms rate ANIP: 2 buy, 2 hold, 0 sell.
- The average price target is $99.50 from 4 analysts, from $85.00 to $119.00.
Updated 2026-11-03 00:00 UTC